The Pharmabiotics Research Institute (PRI) recently convened its annual conference in Brussels, serving as a critical nexus for scientists, clinicians, and industry leaders to discuss the burgeoning field of microbiome science. Among the most significant topics addressed was the emergence of the oral microbiome as a primary indicator of systemic health. Long overshadowed by the gut microbiome, the oral cavity is now recognized as the second most complex microbial ecosystem in the human body, housing a diverse and highly organized community of microorganisms that play a pivotal role in both local and systemic physiology.
During an exclusive interview conducted by Microbiomepost, Gianfranco Grompone, Chief Scientific Officer at BioGaia, detailed the evolving scientific understanding of this ecosystem. The discussion highlighted that the oral microbiome is not a monolithic entity but rather a collection of distinct niches, including the tongue, palate, dental plaque, and saliva. These environments host more than 700 microbial species, comprising bacteria, fungi, and viruses, which are typically organized into resilient structures known as biofilms. When maintained in a state of symbiosis, these microbes contribute to the host’s defense mechanisms; however, a shift toward dysbiosis—often triggered by poor hygiene, diet, or lifestyle factors—can lead to severe inflammatory conditions and broader health complications.
The Evolution of Microbiome Research: From Gut to Mouth
The timeline of microbiome research has historically focused on the gastrointestinal tract, driven by its massive microbial load and its clear links to metabolic and immunological functions. However, the last decade has seen a paradigm shift. The "oral-gut axis" has become a central theme in microbiology, with researchers investigating how oral microbes migrate through the digestive system to influence gut health and beyond.
The Brussels conference highlighted that the oral cavity serves as the gateway to the body. Chronic oral infections, such as periodontitis, do not remain localized. Instead, they provide a constant source of inflammatory mediators and pathogenic bacteria that can enter the bloodstream. The scientific community is increasingly viewing oral microbial signatures as potential proxies for broader systemic health, offering a non-invasive window into a patient’s overall physiological state.
Understanding Oral Dysbiosis and the Biofilm Challenge
The primary challenge in managing oral health lies in the nature of biofilms. Unlike free-floating bacteria, microbes within a biofilm are encased in a self-produced matrix of extracellular polymeric substances. This structure provides a high degree of resistance to physical removal and chemical agents, including antibiotics.
Gianfranco Grompone emphasized that when the oral ecosystem shifts toward dysbiosis, it is often characterized by an overgrowth of periodontal pathogens. This imbalance is the root cause of gingivitis—an early-stage gum inflammation—and periodontitis, a more severe condition involving the destruction of the supporting tissues and bone. Beyond these common ailments, dysbiosis is a major factor in complications following dental procedures. Patients undergoing orthodontic interventions or those with dental implants are at higher risk for peri-implantitis, an inflammatory process that can lead to implant failure if the microbial balance is not managed effectively.
The Oral-Systemic Link: Chronic Diseases and Pathogenic Translocation
One of the most compelling segments of the conference focused on the link between oral pathogens and systemic diseases. The research presented suggests that oral bacteria are not merely bystanders but active contributors to various chronic conditions.
Specific mention was made of Fusobacterium nucleatum, a common oral bacterium that has been frequently cited in recent oncological research. Evidence suggests that F. nucleatum can translocate from the mouth to the colon, where it promotes an inflammatory environment conducive to the development and progression of colorectal cancer. Similarly, the presence of Porphyromonas gingivalis, another key periodontal pathogen, has been detected in the brain tissue of patients with Alzheimer’s disease, suggesting a potential neurological link.
Furthermore, the conference reviewed data associating periodontal disease with type 2 diabetes. The relationship appears to be bidirectional: systemic inflammation from diabetes exacerbates oral health issues, while chronic periodontal inflammation can worsen insulin resistance. This interconnectedness underscores the necessity of a multidisciplinary approach to healthcare that integrates dental and medical interventions.
Probiotics as a Targeted Strategy for Microbiome Modulation
As the limitations of traditional treatments like broad-spectrum antibiotics—which can further disrupt the microbiome—become more apparent, attention has turned to targeted microbial therapies. The use of clinically supported probiotics was a major focal point of the discussions in Brussels.
Grompone detailed the development and application of specific probiotic strains, particularly a synergistic combination of Lactobacillus reuteri strains (DSM 17938 and ATCC PTA 5289). This combination was specifically formulated to address the unique challenges of the oral environment. The mechanism of action is twofold: first, these strains compete with and reduce the burden of periodontal pathogens; second, they modulate the host’s immune response to attenuate inflammatory processes.
The efficacy of this approach is backed by a robust body of evidence. To date, more than 70 randomized controlled trials (RCTs) have been conducted across various indications, including:
- Gingivitis and Periodontitis: Reducing bleeding on probing and pocket depth.
- Peri-implantitis: Managing inflammation around dental implants.
- Dental Plaque and Caries Prevention: Inhibiting the growth of Streptococcus mutans, the primary driver of tooth decay.
The sheer volume of clinical data sets these specific strains apart from generic probiotic supplements, highlighting the industry’s move toward "evidence-based probiotics" where specific strains are matched to specific clinical outcomes.
Industry Perspectives and Official Responses
The shift toward microbiome-based therapies is gaining traction among dental professionals and public health officials. While traditional dentistry has focused on mechanical cleaning and restorative procedures, there is a growing consensus that biological management of the oral ecosystem is required for long-term success.
During the conference, industry experts noted that the integration of probiotics into standard dental care could significantly reduce the reliance on chemical mouthwashes and systemic antibiotics. This is particularly relevant in the context of the global antimicrobial resistance (AMR) crisis. By using beneficial bacteria to suppress pathogens, clinicians can achieve a more sustainable and less invasive form of treatment.
Furthermore, the European regulatory landscape for probiotics remains a topic of intense discussion. Organizations like the PRI are working to bridge the gap between scientific discovery and regulatory approval, ensuring that consumers and healthcare providers have access to products that are both safe and efficacious.
Broader Impact: The Economic and Public Health Implications
The implications of these findings extend far beyond the laboratory. According to the World Health Organization (WHO), oral diseases are among the most common non-communicable diseases globally, affecting nearly 3.5 billion people. The economic burden is staggering, involving both direct treatment costs and indirect costs related to productivity loss.
By shifting the focus from reactive treatment to proactive microbiome management, there is a significant opportunity to reduce the global burden of oral and systemic disease. The conference participants argued that oral health should no longer be viewed in isolation. If oral microbial signatures can indeed serve as early warning signs for conditions like diabetes or colorectal cancer, then the dentist’s office could become a primary site for early disease screening.
Future Outlook: Personalized Oral Microbiome Therapy
As genomic sequencing technology becomes more accessible and affordable, the future of oral health likely lies in personalized medicine. The data presented in Brussels suggests a future where a patient’s oral microbiome is sequenced to identify specific imbalances before symptoms occur. This would allow for highly targeted probiotic interventions tailored to the individual’s unique microbial profile.
The interview with Gianfranco Grompone concluded with a look toward the next frontier: the integration of microbiome science into daily preventive care. As BioGaia and other research-led organizations continue to expand the clinical evidence base, the role of probiotics in maintaining the delicate balance of the oral ecosystem is set to become a cornerstone of 21st-century medicine.
In summary, the Pharmabiotics Research Institute conference in Brussels has reinforced the critical importance of the oral microbiome. Through the synthesis of clinical research, such as the 70+ RCTs on Lactobacillus reuteri, and the identification of clear links between oral dysbiosis and systemic chronic diseases, the scientific community is paving the way for a new era of healthcare. This era will be defined by a deeper understanding of our microbial partners and a more sophisticated approach to maintaining the balance that is essential for human health.